Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 5, 1999, Pages 621-627

  Pong, Alice ^a,b   Thomson, Kenneth S ^a   Moland, Ellen S ^a   Chartrand, Stephen A ^a   Sanders, Christine C ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; DRUG POTENCY; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; QUINOLINES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0032760470     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.5.621     Document Type: Article

References (16)

1. Dalhoff, A. (1994). Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance. Infection 22, Suppl 2, S111-21.
2. Wiedemann, B. & Heisig, P. (1994). Mechanisms of quinolone resistance. Infection 22, Suppl. 2, S73-9.
3. Akaniro, J. C., Stutman, H. R., Arguedas, A. G. & Vargas, O. M. (1992). In-vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients. Antimicrobial Agents and Chemotherapy 36, 255-61.
4. Aldridge, K. E., Jones, R. N., Barry, A. L. & Gelfand, M. S. (1992). In-vitro activity of various antimicrobial agents against Staphylococcus aureus isolates including fluoroquinolone- and oxacillin-resistant strains. Diagnostic Microbiology and Infectious Disease 15, 517-21.
5. Thomson, K. S., Sanders, C. C. & Hayden, M. E. (1991). In-vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrobial Agents and Chemotherapy 35, 2329-34.
6. Bauernfeind, A. (1997). Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. Journal of Antimicrobial Chemotherapy 40, 639-51 (Erratum 41, 672).
7. Brueggemann, A. B., Kugler, K. C. & Doern, G. V. (1997). In-vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Antimicrobial Agents and Chemotherapy 41, 1594-7.
8. Dalhoff, A., Petersen, U. & Endermann, R. (1996). In-vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-25.
9. Fass, R. J. (1997). In-vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Antimicrobial Agents and Chemotherapy 41, 1818-24.
10. Souli, M., Wennersten, C. B. & Eliopoulos, G. M. (1998). In-vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. International Journal of Antimicrobial Agents 10, 23-30.
11. Visalli, M. A., Jacobs, M. R. & Applebaum, P. C. (1997). Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral β-lactams. Antimicrobial Agents and Chemotherapy 41, 2786-9.
12. Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P. & Wise, R. (1997). In-vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 41, 101-6.
13. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Villanova, PA.
14. Thomson, K. S. & Sanders, C. C. (1998). The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. Journal of Antimicrobial Chemotherapy 42, 179-87.
15. Thomson, K. S. & Sanders, C. C. (1994). Dissociated resistance among fluoroquinolones. Antimicrobial Agents and Chemotherapy 38, 2095-100.
16. Thomson, K. S., Moland, E. S. & Sanders, C. C. (1999). Activity of trovafloxacin against antibiotic-resistant pathogens. Infectious Diseases in Clinical Practice 8, Suppl. 1, 57-16.